Research and Markets: Biogen-Idec's and Facet Biotech's Daclizumab: Can It Compete in the Increasingly Crowded Multiple Sclerosis Market?

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/psf6bp/biogenidecs_and) has announced the addition of the "Biogen-Idec's and Facet Biotech's Daclizumab: Can It Compete in the Increasingly Crowded Multiple Sclerosis Market?" report to their offering.

Daclizumab is the active agent in Zenapax (Roche), a humanized antibody that blocks the IL-2 receptor. It was first approved in 1997 for transplant rejection prevention. A phase II study in multiple sclerosis (MS) showed evidence of activity and an interim analysis of a phase IIb trial supported initiation of a phase III program. Postings on clinicaltrials.gov suggest the pivotal DECIDE trial of daclizumab will be a head-to-head comparison against Avonex in early stage patients, with a primary endpoint of relapse prevention. This suggests the companies may try to position the product as a first line agent.

This report analyzes the available evidence for daclizumab's use in MS and its risk/benefit profile. It also explores the question of whether its use would be appropriate for early stage patients. Specifically, the report discusses daclizumab's prospects in this setting in light of the growing competition from so many novel compounds - with improved convenience -- about to enter the MS market in the years ahead.

For more information visit http://www.researchandmarkets.com/research/psf6bp/biogenidecs_and.